Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial

J. Bourhis, A. Auperin, Christian Borel, G. Lefebvre, S. Racadot, Lionnel Geoffrois, Xu Sun, Esma Saâda, Beatriz Cirauqui, Tomasz Rutkowski, Stéphanie Henry, Anouchka Modesto, Alison Johnson, S. Chapet, B. Calderon, C. Sire, O. Malard, Matthieu Bainaud, Antonio Da Silva Motta, SEBASTIEN THUREAU, Y. Pointreau, P. Blanchard, G. Buiret, Laurence Bozec, Stéphane Lopez, Julie Vanbockstael, Matthieu Bosset, Charlotte Greilsamer, Amaury Daste, Antoine Bruna, France N'Guyen, M. Plana, Eluska Iruarrizaga, Stéphane Temam, C. Even, Elisabeth Pérez Ruiz, Mahasti Bert, Eleni Karamouza, Juliette Thariat, Joanna Kazmierska, Amanda Psyrri, Ricard Mesı́a, Y. TAO